Cargando…

Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine

Neuralgic amyotrophy (NA) also known as Parsonage–Turner syndrome is an inflammatory disorder of the brachial plexus characterized by sudden, acute onset of severe pain of the arm and/or shoulder followed by muscle weakness and sensory abnormalities. Although management may involve physical therapy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sedlacek, Carissa M., Leone, Michael, Foster, Adam D., Hinkelman, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035001/
https://www.ncbi.nlm.nih.gov/pubmed/33868407
http://dx.doi.org/10.1155/2021/6663755
_version_ 1783676637223583744
author Sedlacek, Carissa M.
Leone, Michael
Foster, Adam D.
Hinkelman, Amy
author_facet Sedlacek, Carissa M.
Leone, Michael
Foster, Adam D.
Hinkelman, Amy
author_sort Sedlacek, Carissa M.
collection PubMed
description Neuralgic amyotrophy (NA) also known as Parsonage–Turner syndrome is an inflammatory disorder of the brachial plexus characterized by sudden, acute onset of severe pain of the arm and/or shoulder followed by muscle weakness and sensory abnormalities. Although management may involve physical therapy, immunomodulatory drugs, and analgesics, there is nothing specific for the treatment of NA. Full functional recovery can take months to years, but recurrence and/or persistence of symptoms and disability are frequent. This case reports a 22-year-old male who recovered from NA within 3 months following treatment with 1000 mg of methylprednisolone and off-label use of 0.5 g/kg of intravenous immunoglobulins (IVIG) for four consecutive days. Three years later, the patient experienced soreness and paresthesia of the shoulder following a military shooting exercise, and 0.75 g/kg of IVIG and 1000 mg of MP were prescribed for 2 consecutive days resulting in complete recovery and no recurrences to date. EMG findings, 3.5-year postinitial treatment, revealed improvement in the brachial plexopathy. This provides support for the combined use of IVIG and glucocorticoids in the treatment of NA and highlights the need for further studies investigating whether this combined treatment regimen may accelerate recovery and improve long-term outcomes for patients diagnosed with NA.
format Online
Article
Text
id pubmed-8035001
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-80350012021-04-16 Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine Sedlacek, Carissa M. Leone, Michael Foster, Adam D. Hinkelman, Amy Case Rep Med Case Report Neuralgic amyotrophy (NA) also known as Parsonage–Turner syndrome is an inflammatory disorder of the brachial plexus characterized by sudden, acute onset of severe pain of the arm and/or shoulder followed by muscle weakness and sensory abnormalities. Although management may involve physical therapy, immunomodulatory drugs, and analgesics, there is nothing specific for the treatment of NA. Full functional recovery can take months to years, but recurrence and/or persistence of symptoms and disability are frequent. This case reports a 22-year-old male who recovered from NA within 3 months following treatment with 1000 mg of methylprednisolone and off-label use of 0.5 g/kg of intravenous immunoglobulins (IVIG) for four consecutive days. Three years later, the patient experienced soreness and paresthesia of the shoulder following a military shooting exercise, and 0.75 g/kg of IVIG and 1000 mg of MP were prescribed for 2 consecutive days resulting in complete recovery and no recurrences to date. EMG findings, 3.5-year postinitial treatment, revealed improvement in the brachial plexopathy. This provides support for the combined use of IVIG and glucocorticoids in the treatment of NA and highlights the need for further studies investigating whether this combined treatment regimen may accelerate recovery and improve long-term outcomes for patients diagnosed with NA. Hindawi 2021-04-01 /pmc/articles/PMC8035001/ /pubmed/33868407 http://dx.doi.org/10.1155/2021/6663755 Text en Copyright © 2021 Carissa M. Sedlacek et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Sedlacek, Carissa M.
Leone, Michael
Foster, Adam D.
Hinkelman, Amy
Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine
title Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine
title_full Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine
title_fullStr Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine
title_full_unstemmed Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine
title_short Off-Label Use of Intravenous Immunoglobulin with Methylprednisolone to Treat Parsonage–Turner Syndrome in a United States Marine
title_sort off-label use of intravenous immunoglobulin with methylprednisolone to treat parsonage–turner syndrome in a united states marine
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035001/
https://www.ncbi.nlm.nih.gov/pubmed/33868407
http://dx.doi.org/10.1155/2021/6663755
work_keys_str_mv AT sedlacekcarissam offlabeluseofintravenousimmunoglobulinwithmethylprednisolonetotreatparsonageturnersyndromeinaunitedstatesmarine
AT leonemichael offlabeluseofintravenousimmunoglobulinwithmethylprednisolonetotreatparsonageturnersyndromeinaunitedstatesmarine
AT fosteradamd offlabeluseofintravenousimmunoglobulinwithmethylprednisolonetotreatparsonageturnersyndromeinaunitedstatesmarine
AT hinkelmanamy offlabeluseofintravenousimmunoglobulinwithmethylprednisolonetotreatparsonageturnersyndromeinaunitedstatesmarine